EcoDrugPlus

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, B

Ensembl ID : ENSORLG00000013818
Gene Symbol: CACNA1BB
3 Cross references
218 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSORLG00000025805
Gene Symbol: CACNA1AB
4 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSORLG00000003682
Gene Symbol: CACNA2D2A
4 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSORLG00000002991
Gene Symbol: CACNB1
4 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSORLG00000010896
Gene Symbol: CACNB2A
4 Cross references
201 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSORLG00000012349
Gene Symbol: CACNB3A
4 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3b

Ensembl ID : ENSORLG00000006945
Gene Symbol: CACNB3B
3 Cross references
198 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 4 Subunit

Ensembl ID : ENSORLG00000006530
Gene Symbol: CACNB4.1
3 Cross references
68 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSORLG00000013870
Gene Symbol: CACNG1A
4 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5b

Ensembl ID : ENSORLG00000025546
Gene Symbol: CACNG5B
3 Cross references
169 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6b

Ensembl ID : ENSORLG00000011512
Gene Symbol: CACNG6B
3 Cross references
176 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7b

Ensembl ID : ENSORLG00000011496
Gene Symbol: CACNG7B
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).